Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine | Strategic Alliance Partners

Dario R. Roque, MD, discusses incorporating PARP inhibitors into practice for patients with homologous recombination deficient ovarian cancer, the role of PARP inhibitors for patients with homologous recombination–proficient ovarian cancer and the expanding investigation of mirvetuximab soravtansine in ovarian cancer.

William J. Gradishar, MD, discusses the expansion of antibody-drug conjugates across subsets of breast cancer, along with emerging treatment options within each space.

Melissa A. Simon, MD, MPH, discusses unmet needs regarding clinical trials for underserved populations with cancer, highlights the key objectives of the ECOG-ACRIN Health Equity Committee and the US Preventive Services Task Force, and shares her advice to health care professionals in the cancer space who are working to bridge some of these disparities.

Melissa A. Simon, MD, discusses ensuring health equity in cancer care.

Mary F. Mulcahy, MD, discusses the design of the phase 3 EPOCH trial in patients with metastatic colorectal cancer and liver metastases.

The novel antimetabolite aspacytarabine was found to produce a complete remission rate of 37% in adult patients with newly diagnosed acute myeloid leukemia who are unfit for intensive therapy.

Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.

Mary F. Mulcahy, MD, discusses the key takeaways from the ongoing EPOCH trial in patients with colorectal cancer and liver metastases. 

TheraSphere Y-90 glass microspheres offer a precision medicine technique aimed at delivering high-dose radiation directly to tumors.

Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.

William Gradishar, MD, discusses the phase 2 data evaluating the activity with IV cetirizine and its potential use in patients with breast cancer.

William Gradishar, MD, discusses the efficacy of pretreatment with intravenous cetirizine in the prevention of infusion reactions in patients with breast cancer and other malignancies.

Jyoti D. Patel, MD, discusses the evolving use of osimertinib in EGFR-mutant NSCLC and emerging targeted agents for patients with EGFR exon 20 insertion mutations.

Massimo Cristofanilli, MD, highlights the introduction of CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib, which has been a significant addition to the hormone receptor–positive, HER2-negative breast cancer armamentarium.

Al B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.

William J. Gradishar, MD, discusses the expanding role of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Maha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.

Maha Hussain, MD, FACP, FASCO, discusses the need for treatment that elicits an overall survival benefit in patients with nonmetastatic castration-resistant prostate cancer.

Maha H.A. Hussain, MD, FACP, FASCO, discusses the updated findings from the PROfound trial, its clinical significance in the treatment of patients with mCRPC paradigm, and the promise of precision medicine.

William J. Gradishar, MD, discusses the ​current treatment landscape in metastatic HER2-positive breast cancer.

Maha Hussain, MD, FACP, FASCO, discusses the need for collaboration to cure patients with prostate cancer.

Maha H.A. Hussain, MD, FACP, FASCO, discusses the prognostic associations of depth of PSA responses with MFS in patients with nmCRPC and a rapidly rising PSA who have been treated with enzalutamide and other efforts being made in this disease.

Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the clinical impact of the phase 3 PROfound trial in metastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the safety profile of olaparib as observed in the phase 3 PROfound trial in men with metastatic castration-resistant prostate cancer.

William J. Gradishar, MD, discusses the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and stable brain metastases.

Sunandana Chandra, MD, MS, discusses unanswered questions regarding the utility of targeted therapy in melanoma.

Sunandana Chandra, MD, MS, discusses the incidence of targetable mutations in melanoma.

William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.

Reem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.